ACADIA (NASDAQ: ACAD) CEO sells 11,641 shares after RSU vesting

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS Chief Executive Officer Catherine Owen Adams reported routine equity transactions linked to restricted stock unit vesting. On March 24, 2026, she exercised 23,509 restricted stock units, receiving the same number of common shares at a $0.00 conversion price and increasing her direct common stock holdings to 26,444 shares.

On March 25, 2026, she made an open-market sale of 11,641 common shares at $21.47 per share. Footnotes state these mandatory sales were to cover withholding taxes and related items in connection with restricted stock unit vesting and are intended to comply with Rule 10b5-1(c). Following the sale, she directly holds 14,803 common shares and 70,530 restricted stock units, which vest in four equal annual installments beginning March 24, 2026.

Insider Trade Summary

Net Seller: 11,641 shares ($249,932)

Net Sell 3 txns

Insider Owen Adams Catherine

Role Chief Executive Officer

Sold 11,641 shs ($250K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,641	$21.47	$250K
Exercise	Restricted Stock Units	23,509	$0.00	--
Exercise	Common Stock	23,509	$0.00	--

Holdings After Transaction: Common Stock — 14,803 shares (Direct); Restricted Stock Units — 70,530 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Includes 2,935 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The restricted stock units vest in four equal annual installments beginning March 24, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Owen Adams Catherine

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		M		23,509	A	$0(1)	26,444(2)	D
Common Stock	03/25/2026		S(3)		11,641	D	$21.47	14,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/24/2026		M			23,509	(4)	(4)	Common Stock	23,509	$0	70,530	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 2,935 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan.

3. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

4. The restricted stock units vest in four equal annual installments beginning March 24, 2026.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ACAD (ACADIA PHARMACEUTICALS) report for its CEO?

ACAD reported that CEO Catherine Owen Adams exercised 23,509 restricted stock units into common stock, then sold 11,641 common shares. The sale was described as mandatory to cover withholding taxes tied to vesting, under an arrangement intended to comply with Rule 10b5-1(c).

How many ACAD shares did the CEO sell and at what price?

The CEO sold 11,641 shares of ACAD common stock at $21.47 per share. This open-market transaction occurred on March 25, 2026 and, according to footnotes, was a mandatory sale to satisfy withholding taxes and related items on restricted stock unit vesting.

What equity did ACAD’s CEO acquire through restricted stock units in this Form 4?

The CEO exercised 23,509 restricted stock units, receiving 23,509 shares of ACAD common stock at a $0.00 conversion price. Each restricted stock unit represents a contingent right to one common share, and the units vest in four equal annual installments beginning March 24, 2026.

What are the CEO’s ACAD share and restricted stock unit holdings after these transactions?

After the reported transactions, the CEO directly holds 14,803 shares of ACAD common stock and 70,530 restricted stock units. Footnotes also note 2,935 of the common shares were previously acquired under an employee stock purchase plan on May 15, 2025.

Were the ACAD CEO’s share sales discretionary or part of a tax-related plan?

Footnotes state the sales were mandatory and made to cover withholding taxes and tax-related items tied to restricted stock unit vesting. They are intended to comply with Rule 10b5-1(c), indicating a pre-arranged, rule-based structure rather than purely discretionary timing decisions.